HDFC Pharma & Healthcare Fund Delivers 30.19% CAGR, Scheme Bets On India’s Expanding Healthcare Sector
Mumbai: HDFC Mutual Fund has highlighted the performance of its HDFC Pharma and Healthcare Fund, which delivered a compound annual growth rate of 30.19 percent since its launch on October 4, 2023. The sectoral fund also generated a one-year return of 19.01 percent as of July 31, 2026. Its net asset value stood at Rs 21.069 on the same date. Where does the fund invest? The scheme aims to generate…
On October 4, 2023, HDFC Mutual Fund launched the HDFC Pharma and Healthcare Fund, which has since delivered an impressive compound annual growth rate of 30.19 percent. As of July 31, 2026, the fund generated a one-year return of 19.01 percent, with a net asset value of Rs 21.069. This sectoral fund aims to generate long-term capital appreciation by investing primarily in equity and equity-related instruments of pharmaceutical and healthcare companies.
The fund's portfolio encompasses pharmaceuticals, hospitals, healthcare service providers, biotechnology, medical equipment and supplies. It employs a research-led, bottom-up investment approach, allowing it to invest across companies of varying market capitalizations. Nikhil Mathur oversees the management of the HDFC Pharma and Healthcare Fund.
According to HDFC Mutual Fund, India's pharmaceutical and healthcare sector presents a significant growth opportunity. Factors such as rising domestic demand, increasing healthcare expenditure, expanding export opportunities, and India's status as a major global pharmaceutical manufacturing hub are expected to support the sector's long-term prospects.
The fund firm identifies potential in areas such as complex generic medicines, biosimilars, specialty drugs, contract development and manufacturing, hospitals, diagnostics, and medical technology.
Several long-term trends, including an aging population, the growing incidence of lifestyle-related diseases, rising per capita income, and increasing health insurance penetration, could further fuel healthcare spending in India. HDFC AMC Managing Director and Chief Executive Officer Navneet Munot emphasized that the fund house remains committed to identifying businesses well-positioned to capitalize on these long-term trends.
However, it is crucial for investors to recognize that sectoral and thematic schemes, like the HDFC Pharma and Healthcare Fund, carry higher risks compared to diversified equity mutual funds due to their concentrated investments in a specific sector or theme. Past performance does not guarantee future returns, and investors should carefully evaluate their risk tolerance and financial objectives before investing.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
